Translate page

English English
en Englishbg Bulgarianzh-CN Chinese (Simplified)hr Croatiancs Czechda Danishnl Dutchfi Finnishfr Frenchde Germanel Greekiw Hebrewhi Hindiid Indonesianit Italianja Japaneseko Koreanmk Macedonianpl Polishpt Portuguesero Romanianru Russiansr Serbiansk Slovaksl Slovenianes Spanishsv Swedishth Thaitr Turkishvi Vietnamese

Tessa Holyoake

tessa_holyoake

Professor Tessa Holyoake

  • 1980-85 Medicine Glasgow University
  • 1985-86 House jobs Stobhill and Victoria, Glasgow
  • 1986-89 General medical training Inverclyde Hospital, Greenock
  • 1989-92 Haematology, Western Infirmary, Glasgow
  • 1992-96 PhD, Beatson Institute for Cancer Research, Glasgow
  • Specialist Haematology Training, Glasgow Royal Infirmary
  • 1996-98 LRF Senior Lecturer, Terry Fox Labs, Vancouver
  • 1999-2001 Senior Lecturer, Academic Transfusion Medicine Unit, Glasgow Royal Infirmary
  • 2001-2004 Reader, Section of Experimental Haematology, Glasgow Royal
  • 2004-present Professor, Section of Experimental Haematology, Glasgow Royal
  • 2008 Relocation of Section of Experimental Haematology to the Paul O'Gorman Leukaemia Research Centre and West of Scotland Cancer Centre, Gartnavel Hospital

 

Research Interests

My research focuses on the cancer stem cell. Cancer stem cells sustain cancers and leukaemias, are inherently resistant to many cancer therapies, including novel targeted agents and ultimately cause relapse in patients following therapy. We are most interested in the blood cancers, in particular chronic myeloid leukaemia. We have developed laboratory methods to purify the cells of interest from leukaemia patients and from normal donors, allowing side by side comparisons of leukaemic versus normal stem cells. These comparisons include global analyses of gene expression and protein expression. Any differences can then be fully investigated and exploited through drug discovery. Recently we have begun to explore high throughput drug screening against the purified cancer stem cells hoping to find drugs that rapidly kill the cancer stem cells but leave normal stem cells intact.
On the clinical side I run clinical trials of novel agents for patients with CML Scotland wide.

 

Francisco Cervantes

Francisco Cervantes is senior consultant at the Hematology Department of the Hospital Clínic, in Barcelona, Spain, and associate professor at the University of Barcelona. His main scientific interest is the study of chronic myeloid leukemia (CML) and the Ph-negative chronic myeloproliferative neoplasms (MPNs), mainly their natural history, prognosis, biology, and treatment. As a result of the activity in this field, he has published more than 190 articles in peer-review international journals, including the New England Journal of Medicine, Blood, Journal of Clinical Oncology, Leukemia, British Journal of Haematology, Experimental Hematology, Haematologica, Cancer, Oncogene, Seminars in Oncology, and the European Journal of Haematology. In the CML field, Dr. Cervantes contributed to the elaboration of Sokal’s score, is a coauthor of the publications of the IRIS study, which established imatinib as first-line treatment for CML, has participated in the introduction of the second-generation tyrosine kinase inhibitors for patients resistant to imatinib, as well as in the authorship of the European LeukemiaNet recommendations for the treatment of CML. His more recent contributions in the field of the MPNs have been the elaboration of the new prognostic classification of primary myelofibrosis on behalf of the International Working Group for Myelofibrosis Research and Treatment, as well as several studies on the role of leukocyte and platelet activation in the thrombosis of MPN patients. At local level, he is the national coordinator of the CML studies within the collaborative PETHEMA Spanish group. Dr Cervantes is a member of the American Society of Hematology, the European Hematology Association, the International Working Group for Myeloproliferative Neoplasms Research and Treatment, the European Leukemianet, and the Spanish Society of Hematology.